ARTICLE | Clinical News
Seattle Genetics begins Phase II trial
November 30, 2000 8:00 AM UTC
Seattle Genetics (Bothell, Wash.) began a U.S. Phase II trial of its SGN-15 (BR96) monoclonal antibody against the Lewis Y antigen that is chemically linked to doxorubicin, in combination with Aventis...